Long-term Metastatic Melanoma Survival Dramatically Improves on Immunotherapy
About half of metastatic melanoma patients treated with immune checkpoint inhibitors survive cancer-free for 10+ years, according to a 10-year follow-up study from Dana-Farber Cancer Center and Weill Cornell Medicine. The CheckMate 067 trial, involving 945 patients, showed combining nivolumab and ipilimumab significantly improved outcomes. The study found no new safety concerns and suggests long-term treatment success.
Reference News
About half of metastatic melanoma patients treated with immune checkpoint inhibitors survive cancer-free for 10+ years, according to a 10-year follow-up study from Dana-Farber Cancer Center and Weill Cornell Medicine. The CheckMate 067 trial, involving 945 patients, showed combining nivolumab and ipilimumab significantly improved outcomes. The study found no new safety concerns and suggests long-term treatment success.